NO983474L - Ekspresjon av gruppe B Neisseria meningitidis ytre membran (MB3) protein fra gjµr og vaksiner - Google Patents
Ekspresjon av gruppe B Neisseria meningitidis ytre membran (MB3) protein fra gjµr og vaksinerInfo
- Publication number
- NO983474L NO983474L NO983474A NO983474A NO983474L NO 983474 L NO983474 L NO 983474L NO 983474 A NO983474 A NO 983474A NO 983474 A NO983474 A NO 983474A NO 983474 L NO983474 L NO 983474L
- Authority
- NO
- Norway
- Prior art keywords
- group
- protein
- yeast
- outer membrane
- meningococcal
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 239000012528 membrane Substances 0.000 title 2
- 241000588650 Neisseria meningitidis Species 0.000 title 1
- 150000004676 glycans Chemical class 0.000 abstract 3
- 229920001282 polysaccharide Polymers 0.000 abstract 3
- 239000005017 polysaccharide Substances 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 101710116435 Outer membrane protein Proteins 0.000 abstract 2
- 108010013381 Porins Proteins 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 102000007739 porin activity proteins Human genes 0.000 abstract 2
- 108020004705 Codon Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1097296P | 1996-02-01 | 1996-02-01 | |
| US2044096P | 1996-06-13 | 1996-06-13 | |
| PCT/US1997/001687 WO1997028273A1 (en) | 1996-02-01 | 1997-01-31 | Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO983474D0 NO983474D0 (no) | 1998-07-28 |
| NO983474L true NO983474L (no) | 1998-09-30 |
Family
ID=26681820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO983474A NO983474L (no) | 1996-02-01 | 1998-07-28 | Ekspresjon av gruppe B Neisseria meningitidis ytre membran (MB3) protein fra gjµr og vaksiner |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0877816A1 (xx) |
| JP (1) | JP2001508758A (xx) |
| KR (1) | KR19990082265A (xx) |
| AU (1) | AU2115897A (xx) |
| HU (1) | HUP9901039A2 (xx) |
| IL (1) | IL125420A0 (xx) |
| NO (1) | NO983474L (xx) |
| PL (1) | PL328096A1 (xx) |
| WO (1) | WO1997028273A1 (xx) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9811475A (pt) | 1997-07-17 | 2000-08-15 | North American Vaccine Inc | Conjugados imunogênicos compreendendo uma porina meningocóccica de grupo b e um polissacarìdeo de h. influenzae |
| EP2261354A3 (en) | 1998-05-01 | 2012-01-11 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| JP4524816B2 (ja) * | 1998-07-06 | 2010-08-18 | 東ソー株式会社 | Ｉｌ−６レセプター・ｉｌ−６直結融合蛋白質 |
| DE69927375T2 (de) * | 1998-07-06 | 2006-06-22 | Tosoh Corp., Shinnanyo | Fusionsprotein mit direkter verknüpfung des il-6-rezeptors mit il-6 |
| GB9818004D0 (en) * | 1998-08-18 | 1998-10-14 | Smithkline Beecham Biolog | Novel compounds |
| AU4309600A (en) | 1999-04-30 | 2000-11-17 | Chiron S.R.L. | Conserved neisserial antigens |
| SK16022001A3 (sk) | 1999-05-13 | 2002-09-10 | American Cyanamid Company | Adjuvantné kombinované prostriedky |
| ES2563650T3 (es) | 1999-05-19 | 2016-03-15 | Glaxosmithkline Biologicals Sa | Composiciones de combinaciones de Neisseria |
| EP1069133A1 (en) * | 1999-07-13 | 2001-01-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Neisseria meningitidis compounds and anti-infection applications thereof |
| AU1875301A (en) * | 1999-11-29 | 2001-06-04 | Chiron S.P.A. | 85kda neisserial antigen |
| GB9928196D0 (en) * | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
| DE60142772D1 (de) | 2000-01-17 | 2010-09-23 | Novartis Vaccines & Diagnostic | Membranvesikel (omv) impfstoff, der n. meningitidis serogruppe b membranproteine enthält |
| CA2875231A1 (en) | 2000-02-28 | 2001-09-07 | Novartis Vaccines And Diagnostics S.R.L. | Heterologous expression of neisserial proteins |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| EP1549338B1 (en) | 2002-10-11 | 2010-12-22 | Novartis Vaccines and Diagnostics S.r.l. | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
| ES2383175T3 (es) | 2003-01-30 | 2012-06-18 | Novartis Ag | Vacunas inyectables contra múltiples serogrupos de meningococos |
| JP2006262846A (ja) * | 2005-03-25 | 2006-10-05 | Niigata Bio Research Park Kk | 酵母による２−デオキシ−シロ−イノソースの合成および精製する方法並びに得られた２−デオキシ−シロ−イノソース |
| KR100919704B1 (ko) * | 2007-09-12 | 2009-10-06 | 한국생명공학연구원 | 효모에서 재조합단백질을 고효율로 분비발현시키는 방법 |
| JP2011116658A (ja) * | 2008-03-13 | 2011-06-16 | Chemo-Sero-Therapeutic Research Inst | 豚萎縮性鼻炎用薬剤の製造方法 |
| US9974848B2 (en) | 2013-11-14 | 2018-05-22 | Duke University | Tetanus toxoid and CCL3 improve DC vaccines |
| CN106146679B (zh) * | 2015-04-23 | 2019-02-01 | 中国医学科学院医学生物学研究所 | 一种纯化细菌荚膜多糖的方法 |
| BR112018013376A2 (pt) * | 2015-12-30 | 2018-12-18 | Dsm Ip Assets Bv | hidrólise enzimática parcial de triacilgliceróis |
| WO2020215017A1 (en) | 2019-04-17 | 2020-10-22 | Impossible Foods Inc. | Materials and methods for protein production |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4356170A (en) * | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| NZ239643A (en) * | 1990-09-17 | 1996-05-28 | North American Vaccine Inc | Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group. |
| US5268273A (en) * | 1990-12-14 | 1993-12-07 | Phillips Petroleum Company | Pichia pastoris acid phosphatase gene, gene regions, signal sequence and expression vectors comprising same |
| US5439808A (en) * | 1993-07-23 | 1995-08-08 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
-
1997
- 1997-01-31 IL IL12542097A patent/IL125420A0/xx unknown
- 1997-01-31 KR KR1019980705994A patent/KR19990082265A/ko not_active Application Discontinuation
- 1997-01-31 JP JP52788197A patent/JP2001508758A/ja active Pending
- 1997-01-31 HU HU9901039A patent/HUP9901039A2/hu unknown
- 1997-01-31 AU AU21158/97A patent/AU2115897A/en not_active Abandoned
- 1997-01-31 PL PL97328096A patent/PL328096A1/xx unknown
- 1997-01-31 WO PCT/US1997/001687 patent/WO1997028273A1/en not_active Application Discontinuation
- 1997-01-31 EP EP97906470A patent/EP0877816A1/en not_active Ceased
-
1998
- 1998-07-28 NO NO983474A patent/NO983474L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL328096A1 (en) | 1999-01-04 |
| NO983474D0 (no) | 1998-07-28 |
| JP2001508758A (ja) | 2001-07-03 |
| WO1997028273A1 (en) | 1997-08-07 |
| AU2115897A (en) | 1997-08-22 |
| HUP9901039A2 (hu) | 1999-07-28 |
| EP0877816A1 (en) | 1998-11-18 |
| KR19990082265A (ko) | 1999-11-25 |
| IL125420A0 (en) | 1999-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO983474L (no) | Ekspresjon av gruppe B Neisseria meningitidis ytre membran (MB3) protein fra gjµr og vaksiner | |
| Matsuo et al. | Establishment of a foreign antigen secretion system in mycobacteria | |
| Ellis | Vaccines: New approaches to immunological problems | |
| JP4827196B2 (ja) | 髄膜炎菌類タンパク質ｎｍｂ１８７０のドメインおよびエピトープ | |
| JP3633933B2 (ja) | 弱毒化細菌における組換え融合タンパク質の発現 | |
| CN101691405B (zh) | 用作疫苗的融合抗原 | |
| Ellis | New technologies for making vaccines | |
| CA1338705C (en) | Vaccines obtained from antigenic gene products of recombinant genes | |
| US8337857B2 (en) | Chimeric poly peptides and the therapeutic use thereof against a Flaviviridae infection | |
| JPH03502687A (ja) | レスピラトリイ・シンシチアル・ウイルス：ワクチンおよび診断法 | |
| GB9224584D0 (en) | Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases | |
| EP0437604B1 (en) | Recombinant poxvirus and streptococcal m protein vaccine | |
| US20100255033A1 (en) | Non-toxic double mutant forms of pertussis toxin as adjuvants | |
| JP2002507396A5 (xx) | ||
| Taubman et al. | Diepitopic construct of functionally and epitopically complementary peptides enhances immunogenicity, reactivity with glucosyltransferase, and protection from dental caries | |
| US7902349B2 (en) | Nucleic acids encoding protective epitopes of adenyl cyclase-haemolysin (AC-Hly) | |
| WO2022003119A1 (en) | Cross-reactive coronavirus vaccine | |
| ES2236718T3 (es) | Proteina portadora de efecto adyuvante, complejo inmunogenico que la contiene, su procedimiento de preparacion, secuencia nucleotidica y vacuna. | |
| JP2011103893A (ja) | 組換えインフルエンザ菌アドヘシンタンパク質 | |
| JPH05213995A (ja) | Ｂ型肝炎ウイルスコア抗原のアミノ酸残基配列 | |
| JPS6117523A (ja) | 淋疾のための広域スペクトルワクチン | |
| EP0320866A2 (en) | A protective immunodominant epitope included in the S1 subunit of pertussis toxin | |
| Chen et al. | A nontoxic Pseudomonas exotoxin A induces active immunity and passive protective antibody against Pseudomonas exotoxin A intoxication | |
| AU751646B2 (en) | Hepatitis B virus polypeptides | |
| KR20080106985A (ko) | Ｎｍｂ0938 단백질을 포함하는 약학적 조성물 |